Immunic Appoints Jon Congleton to Board of Directors

Immunic, Inc., a Nasdaq-listed biotechnology company, has announced the appointment of Jon Congleton to its Board of Directors as of March 27, 2026. Mr. Congleton brings nearly 40 years of experience in biopharmaceuticals, particularly in drug development and commercialization within the central nervous system (CNS) sector.

During his career, he worked on the U.S. launch of Teva Pharmaceuticals’ Copaxone®, a leading treatment for multiple sclerosis (MS). Currently, he serves as CEO of Mineralys Therapeutics, where he transitioned the company to a public biotech entity. His leadership roles also include positions at Impel NeuroPharma and Nivalis Therapeutics.

Immunic's Interim Chairperson, Simona Skerjanec, expressed enthusiasm about Mr. Congleton’s addition, noting his expertise will support advancements in vidofludimus calcium, the company's primary MS program. Mr. Congleton views the role as a key opportunity to influence MS treatment development.